<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543136</url>
  </required_header>
  <id_info>
    <org_study_id>CP323</org_study_id>
    <nct_id>NCT04543136</nct_id>
  </id_info>
  <brief_title>Investigation of Non-CE Marked Intermittent Catheters.</brief_title>
  <official_title>Exploratory Investigation on Performance and Safety of Newly Developed Intermittent Catheters in Male Users of Intermittent Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of non-CE marked intermittent catheters. The study is a randomized, single&#xD;
      blinded, cross-over investigation comparing two new catheters with a comparator catheter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CP323 study is an investigation of non-CE marked intermittent catheters (IC) which will&#xD;
      be conducted in Denmark. The study is a randomized, single blinded, cross-over investigation&#xD;
      comparing two new catheters with a comparator catheter in 15 male IC users.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 16, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Residual urine at 1st clogging</measure>
    <time_frame>Immediately after procedure/catherterization</time_frame>
    <description>Volume of residual urine at 1st clogging assessed by a pressure sensor with time-logged weighing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual urine post catheterisation</measure>
    <time_frame>Immediately after procedure/catherterization</time_frame>
    <description>Volume of residual urine post catheterization assessed by ultrasound scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discomfort</measure>
    <time_frame>Immediately after procedure/catherterization</time_frame>
    <description>Discomfort measured using Visual Analogue Scale (VAS). A tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain/discomfort is a straight line of 10 cm with one end meaning no pain/discomfort and the other end meaning the worst pain/discomfort imaginable. The subject marks a point on the line that matches the amount of pain/discomfort he or she feels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Retention, Urinary</condition>
  <arm_group>
    <arm_group_label>SpeediCath® standard Male</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New intermittent catheter variation 1 for male</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New intermittent catheter variation 1 for male.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New intermittent catheter variation 2 for male</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New intermittent catheter variation 2 for male</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>New intermittent catheters variation 1 and 2 for males</intervention_name>
    <description>The new catheters are not named at this point but are intended for intermittent drainage of the bladder.</description>
    <arm_group_label>New intermittent catheter variation 1 for male</arm_group_label>
    <arm_group_label>New intermittent catheter variation 2 for male</arm_group_label>
    <arm_group_label>SpeediCath® standard Male</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male&#xD;
&#xD;
          2. Is at least 18 years of age and has full legal capacity&#xD;
&#xD;
          3. Has given written informed consent, signed letter of authority and signed secrecy&#xD;
             agreement&#xD;
&#xD;
          4. Should have used an intermittent catheter bladder management method daily, with at&#xD;
             least 2 catheters used in average per day, during the last 3 months&#xD;
&#xD;
          5. Ability to self-catheterise&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in any other clinical study during this investigation&#xD;
&#xD;
          2. Symptoms of urinary tract infection as judged by the investigator&#xD;
&#xD;
          3. Any know allergies towards ingredients in the products&#xD;
&#xD;
          4. Relevant medical history that would prevent the subject to participate in the&#xD;
             investigation (investigators judgement)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Bagi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blegdamsvej 9, Urologisk klinik Afsnit 2112, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanne L. Gotfredsen, PhD</last_name>
    <phone>+4549113350</phone>
    <email>dkjoat@coloplast.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stine Haandbæk Sommersdahl</last_name>
    <phone>+4549113299</phone>
    <email>dksths@coloplast.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blegdamsvej 9, Urologisk klinik Afsnit 2112, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Per Bagi, MD</last_name>
      <phone>+45 35 45 21 11</phone>
      <email>Per.Bagi@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Rikke Permild</last_name>
      <phone>+45 35 45 21 11</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

